Yifan Pharmaceutical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

An integrated pharma company with a commercial portfolio and R&D pipeline in cardiovascular and metabolic diseases.

CardiovascularMetabolic Disease

Integrated capabilities in small molecule synthesis and biologic process development for biosimilars and novel drugs.

The large and growing prevalence of cardiovascular disease in China offers a substantial market for both its established and pipeline products.

Intense government-led price pressure on generic and off-patent drugs in China threatens its core revenue streams.

Competes with large domestic pharma peers in generics and faces innovation competition from more nimble biotechs.